Table 1. Significantly altered serum proteins during neoadjuvant therapy.
Post-NACT | Post-CRT | Evaluation | |||||||
---|---|---|---|---|---|---|---|---|---|
ADIPOQ | 1.15 | ACVR1 | 1.10 | IGFBP3 | 1.21 | ADIPOQ | 1.10 | GRN | 1.12 |
ANG | 1.21 | ADIPOQ | 1.10 | IGFBP7 | 1.12 | ANG | 1.11 | IGF2 | 1.21 |
IGFBP2 | 1.15 | ANG | 1.21 | IL1RAPL2 | 1.10 | ANGPT2 | 1.16 | IGFBP7 | 1.15 |
IL6ST | 1.12 | BMPR1A | 1.11 | IL27 | 1.12 | BDNF | 1.11 | IL1RAPL2 | 1.11 |
NCAM1 | 1.12 | CCL1 | 1.11 | IL6ST | 1.17 | BMPR1A | 1.18 | IL22 | 1.12 |
SAA1 | 1.15 | CCL11 | 1.12 | LBP | 1.16 | CCL11 | 1.14 | IL6ST | 1.12 |
TNFRSF11B | 1.34 | CCL22 | 1.13 | LEPR | 1.11 | CCR6 | 1.14 | LIFR | 1.12 |
CCR6 | 1.10 | PLAU | 1.12 | CD14 | 1.13 | MMP2 | 1.10 | ||
CD14 | 1.14 | RARRES2 | 1.12 | CSF1 | 1.19 | NGFB | 1.12 | ||
CSF1 | 1.22 | RELT | 1.11 | CTF1 | 1.12 | NTF4 | 1.13 | ||
EGFR | 1.11 | SAA1 | 1.27 | CXCR1 | 1.19 | RARRES2 | 1.23 | ||
ERBB2 | 1.20 | SIGLEC5 | 1.14 | CXCR5 | 1.11 | SIGLEC9 | 1.12 | ||
FLT3LG | 1.11 | SIGLEC9 | 1.13 | CXCR6 | 1.12 | SLC2A2 | 1.19 | ||
GCG | 1.13 | SLC2A2 | 1.13 | ERBB2 | 1.11 | THBS4 | 1.12 | ||
GRN | 1.16 | TGFBR1 | 1.11 | ERBB4 | 1.11 | TNFRSF11B | 1.16 | ||
IGF2 | 1.18 | THBS4 | 1.10 | FLT3LG | 1.12 | ||||
IGFBP2 | 1.15 | TNFRSF11B | 1.65 | ||||||
LCN2 | 0.65 | CHRDL2 | 0.88 | PDGFA | 0.86 | CHRDL2 | 0.86 | PDGFA | 0.88 |
LTBP1 | 0.87 | CXCL2 | 0.88 | PDGFB | 0.89 | FGF13 | 0.84 | S100A12 | 0.84 |
MMP9 | 0.63 | FGF13 | 0.83 | PF4 | 0.85 | LCN2 | 0.84 | TMEFF2 | 0.89 |
LCN2 | 0.73 | PPBP | 0.83 | MMP9 | 0.74 | ||||
LTBP1 | 0.80 | S100A12 | 0.85 | ||||||
MMP9 | 0.68 | THBS1 | 0.84 |
Array values of the proteins were transformed to natural logarithms. The fold-change increase or decrease following induction neoadjuvant chemotherapy (post-NACT) and sequential chemoradiotherapy (post-CRT) and at evaluation of the neoadjuvant treatment, relative to baseline, is indicated on the right of each protein. Proteins are listed by their gene names (TNFRSF11B, in italic, corresponds to osteoprotegerin).